

Index

A

- Aardvark, 189
- Able, 206
- AC. *See* Arrhythmic cardiomyopathy
- Actin. *See* F-Actin
- ADAM10, 113
- Adherens junction (AJ). *See also* E-Cadherin
 - axon guidance
 - ephrin regulation, 112–114
 - netrin regulation, 120–122
 - overview, 109–110
 - semaphorin regulation, 117
 - Slit/Robo regulation, 125–127
 - cadherin/catenin complex
 - adapter protein interplay, 12
 - components and regulation, 10–12
 - core complex, 3–5
 - dynamics, 12–14
 - force-dependent anchoring to F-actin, 8–10
 - prospects for study, 14
 - cadherin classification, 325–326
 - cadherin clustering
 - F-actin association, 6–8
 - microclusters, 6–8
 - overview, 5–6
 - cell migration functional overview, 166–167
 - composition and structure, 186
 - desmosome cross talk in adhesive strength
 - modulation, 94–95
 - developmental interactions with other junctions, 191–192
 - endothelial junctions
 - cerebral cavernous malformation defects, 316–318
 - interacting proteins
 - EPS8, 311
 - G α 13, 310–311
 - HEG1, 311–312
 - Trio, 310
 - YAP, 311
 - prospects for study, 318–319
 - small GTPases
 - inflammation effects, 314–316
 - Rap1, 313–314
 - VE-cadherin
 - overview, 308–310
 - Tie2 interactions, 313
 - tyrosine kinase receptor interactions, 312–313
 - VE-PTP interactions, 313
 - epidermis modeling of mechanics and signaling
 - basal to suprabasal transition, 196–197
 - cell shape, positioning and differentiation, 198
 - overview, 195–196
 - SG3 to SG2 tight junction transition, 197–198
 - epithelium
 - intestinal epithelium cell proliferation, 144, 146–148
 - keratinocyte proliferation role, 152
 - overview, 140
 - skin homeostasis, 151–152
 - wound healing, 152–153
 - evolution
 - cytoskeletal linker proteins, 189–191
 - receptors, 188–189
 - Hippo signaling modulation
 - Ajuba, 42
 - cadherin/catenin core complex, 42
 - loss of adherens junctions effects, 43–44
 - NF2, 43
 - overview, 41–42
 - Pez, 43
 - PTPN14, 43
 - history of study, 2–3
 - receptor tyrosine kinase local impact on junctions, 206–207, 209
 - vessel maintenance, 229–230
- AFM. *See* Atomic force microscopy
- AIP4, 39
- AJ. *See* Adherens junction
- Ajuba, 21, 30, 42, 66
- AKT, 336–338
- α -Catenin. *See also* Adherens junction
 - cadherin/catenin complex in adherens junction
 - adapter protein interplay, 12
 - components and regulation, 10–12
 - core complex, 3–5
 - dynamics, 12–14
 - force-dependent anchoring to F-actin, 8–10
 - mechanosensing, 61–63
 - mechanotransduction consequences
 - early, 64–65
 - late, 65–66
 - prospects for study, 14
 - cancer defects, 330–331
 - evolution, 189
 - history of study, 3

Index

- α 2-Chimerin, 169
 - Amot. *See* Angiominotin
 - AMOTL1. *See* Angiominotin-like-1
 - AMOTL2. *See* Angiominotin-like-2
 - Ang1, 226, 230
 - Angiogenesis. *See also* Vascular remodeling
 - anastomosis, 223–224
 - lumen formation
 - apico-basal polarity orchestration, 225–226
 - junctional actin, 227
 - junctional rearrangements, 224–225
 - overview, 219–221
 - sprouting
 - dynamic remodeling of junctions, 221
 - front–rear polarity and collective migration coordination, 222
 - strands, 171
 - VE-cadherin
 - actin cytoskeleton organization and sprout elongation, 222
 - cessation of sprouting, 224
 - vascular endothelial growth factor regulation of turnover, 221
 - vessel maintenance by adherens junctions, 229–230
 - Angiominotin (Amot), Hippo signaling modulation, 38, 39–40, 46–47, 222
 - Angiominotin-like-1 (AMOTL1), 222
 - Angiominotin-like-2 (AMOTL2), 227
 - AP-1, 80–81, 96
 - AP-2, E-cadherin recycling studies, 73, 75, 80
 - AP1B, 210
 - APC, 146–147
 - aPKC. *See* Atypical protein kinase C
 - APKD. *See* Autosomal polycystic kidney disease
 - ARF6, 206
 - Arf6, 113, 127
 - ArhGAP21, 31
 - ArhGAP29, 314
 - Armadillo, 187, 189
 - Arp2/3, 121, 222
 - Arrhythmogenic cardiomyopathy (AC), 93
 - Ask1, 265
 - Atomic force microscopy (AFM), keratinocyte studies, 99, 101
 - Atypical protein kinase C (aPKC)
 - Atypical protein kinase C
 - angiogenesis, 225–226
 - E-cadherin endocytosis role of atypical protein kinase C polarity module, 74, 76–78
 - Hippo signaling modulation by atypical protein kinase C polarity module, 38, 40
 - Autosomal polycystic kidney disease (APKD), 210
 - Axon guidance
 - adherens junctions
 - ephrin regulation, 112–114
 - netrin regulation, 120–122
 - overview, 109–110
 - semaphorin regulation, 117
 - Slit/Robo regulation, 125–127
 - gap junctions
 - ephrin regulation, 114
 - netrin regulation, 122–123
 - overview, 110
 - semaphorin regulation, 118
 - tight junctions
 - ephrin regulation, 114
 - netrin regulation, 122
 - overview, 110
 - semaphorin regulation, 117–118
 - Slit/Robo regulation, 127–128
- ## B
- BAD, 336
 - Balance. *See* Hair cell
 - BCL2, 335, 338
 - β -Catenin. *See also* Adherens junction
 - adherens junction cadherin/catenin complex
 - adapter protein interplay, 12
 - components and regulation, 10–12
 - core complex, 3–5
 - dynamics, 12–14
 - force-dependent anchoring to F-actin, 8–10
 - mechanosensing, 61–63
 - mechanotransduction consequences
 - early, 64–65
 - late, 65–66
 - prospects for study, 14
 - epithelial-to-mesenchymal transition, 263
 - evolution, 189
 - history of study, 3
 - neurogenesis, 280
 - T-cell factor signaling, 262, 265
 - BIM, 336–337
 - BME, 336
 - Bnip-2, 265
 - Breast cancer, E-cadherin studies
 - epithelial-to-mesenchymal transition, 329–330
 - loss
 - α -catenin loss, 330–331
 - biochemical consequences, 334–335
 - p120 loss, 331
 - therapeutic targeting, 335–338
 - tumor development and progression, 328–329
 - mammary gland function, 326–328
- ## C
- Cadherin. *See also* Adherens junction; *specific cadherins*
 - adherens junction cadherin/catenin complex
 - adapter protein interplay, 12

- components and regulation, 10–12
 - core complex, 3–5
 - dynamics, 12–14
 - F-actin association, 6–8
 - force-dependent anchoring to F-actin, 8–10
 - mechanosensing, 61–63
 - mechanotransduction consequences
 - early, 64–65
 - late, 65–66
 - microclusters, 6–8
 - overview, 5–6
 - prospects for study, 14
 - classification, 325–326
 - Cadherin-7, 283
 - Cadherin-9, 285
 - Cadherin-11, 285, 334
 - Cadherin-23 (CDH23)
 - genetic determinants of function, 245–247
 - hair cell mechanotransduction overview, 236–238
 - mutations and diseases, 247–248
 - structural determinants of function, 239–241
 - Cancer invasion
 - cell sheet and cluster migration, 171–172
 - collective migration and tuning, 175–176
 - Caspase, 57
 - CCM. *See* Cerebral cavernous malformation
 - CCM1, 226, 311, 314, 316–318
 - CCM2, 226, 311, 316–318
 - CCM3, 311, 316–318
 - CD146, 221
 - Cdc42, 27, 29–30, 74, 76–78, 167, 225, 265
 - CdGAP, 29
 - CDH23. *See* Cadherin-23
 - Cdon, 265–267
 - CeldR, 188
 - Celsr, 186, 281, 284
 - Cerebellin, 119
 - Cerebral cavernous malformation (CCM), 226, 316–319
 - CFTR, 293
 - Charcot-Marie-Tooth disease, 349
 - Cip4, 77
 - CK2, 300–301
 - Claudin, 139, 143, 147
 - Claudin-2, 294, 299, 301
 - Claudin-5, 127
 - Claudin-8, 294
 - Claudin-13, 296
 - Claudin-15, 294
 - Claudin-18, 294
 - Cochlear inner hair cell. *See* Hair cell
 - Connexins. *See* Gap junction; *specific Cxs*
 - Cortactin, 113
 - CRB, 225
 - CRB3, 39
 - Crumbs, Hippo signaling modulation, 38–39, 46
 - c-SRC, 221
 - Ctip-2, 153
 - Cx26, 349, 351–353
 - Cx29, 350
 - Cx30, 349–353
 - Cx31, 352
 - Cx32, 349–350
 - Cx36, 350
 - Cx37, 350
 - Cx40, 350, 353
 - Cx43, 346–354
 - Cx45, 350
 - Cx47, 349–350
 - Cytokeratin, 151
- ## D
- Dab-2, E-cadherin recycling studies, 73
 - Dachsous, Hippo signaling modulation, 41
 - Dachsous1, 281
 - Deafness, connexin mutations, 352–353
 - Delta, 263–264
 - Desmoplakin (DP), 150, 189–190, 193–194, 333
 - Desmosome
 - actin-based junction regulation in epidermis, 194
 - adhesive strength
 - actin organization, 95
 - adherens junction cross talk in modulation, 94–95
 - hyperadhesion, 93–94
 - isoform dependence, 93
 - cancer defects, 333
 - composition and structure, 90–92, 186–187
 - developmental interactions with other junctions, 191–192
 - epidermis modeling of mechanics and signaling
 - basal to suprabasal transition, 196–197
 - cell shape, positioning and differentiation, 198
 - overview, 195–196
 - SG3 to SG2 tight junction transition, 197–198
 - epithelium
 - epidermal barrier function, 147, 149–151
 - overview, 140–141
 - evolution
 - cytoskeletal linker proteins, 189–191
 - receptors, 188–189
 - mechanotransduction, 95–96, 102
 - pathology, 92–93
 - DLC2, 31
 - Dlg, 83
 - DP. *See* Desmoplakin
 - Draxin, 119
 - DSC1, 91–92, 149, 191
 - DSC2, 91–92, 94, 141, 191
 - DSC3, 91–92, 193
 - DSCAM, 120

Index

- DSG1, 91–92, 98, 100, 193–195
DSG2, 91, 94, 191, 193, 333
DSG3, 91, 149, 191, 333
DSG4, 91
Dynamin, 73, 77
- E**
- EB1, 123
- E-Cadherin. *See also* Adherens junction
cadherin/catenin complex, 71–72
clathrin-mediated endocytosis
 localization regulation, 76–78
 overview, 73–75
 p120 catenin inhibition, 75
 posttranslational modifications in regulation,
 75–76
endosomal sorting, 78–79
gastrointestinal cancer mutations, 146
Hippo signaling modulation, 41, 44
intestinal mucosa, 293–294
loss
 cancer
 α -catenin loss, 330–331
 biochemical consequences, 334–335
 p120 loss, 331
 tumor development and progression,
 328–329
 epithelial-to-mesenchymal transition, 329–330
 therapeutic targeting, 335–338
 mammary gland function, 326–328
 mechanical force, 57–58, 63
 Rab11 endosomes
 recycling role, 79
 sorting of newly synthesized E-cadherin, 80–81
 Rab11 exocyst in polarized exocytosis, 79–80
 wound healing, 152–153
- Ect2, 30–31, 315
- Ectodermal dysplasia-skin fragility syndrome
(EDSFS), 92
- Ed, 43
- EDSFS. *See* Ectodermal dysplasia-skin fragility
 syndrome
- EGF. *See* Epidermal growth factor
- EGFR. *See* Epidermal growth factor receptor
- EMT. *See* Epithelial-to-mesenchymal transition
- Ena, 45, 64, 284
- Endothelial cell junctions. *See* Adherens junction;
 Angiogenesis; VE-Cadherin
- Epac, 314
- EPAC1, 316
- EPAC2, 316
- EphA, 110, 113–114
- EphB, 110, 113–114
- Ephexin, 169
- Ephrin signaling
- adherens junction regulation, 112–114
 cell migration functional overview, 169
 gap junction regulation, 114
 muscle fiber type patterning, 269–270
 neurogenesis, 278
 signaling overview, 110–112
 tight junction regulation, 114
- Epidermal growth factor (EGF), 75, 110, 209, 213
- Epidermal growth factor receptor (EGFR), 153, 188,
 195, 198, 207, 209–210, 213–214,
 336–337
- Epidermis
- adherens junctions
 cell proliferation, 152
 skin homeostasis, 151
- barrier function of tight junctions and desmosomes,
 147–151
- intestinal epithelium cell–cell junction comparison,
 153–154
- junction coordination of organization, growth, and
 differentiation
 desmosome regulation of actin-based junctions,
 194
 modeling of adherens junction and desmosome
 mechanics and signaling
 basal to suprabasal transition, 196–197
 cell shape, positioning and differentiation,
 198
 overview, 195–196
 SG3 to SG2 tight junction transition,
 197–198
 overview, 193–194
 SG2 tight junction barrier formation, 194
 signaling and differentiation regulation,
 194–195
- keratinocyte migration and cell–cell junctions, 152
- wound healing
 adherens junction role, 152–153
 Hippo signaling, 153
- Epithelial-to-mesenchymal transition (EMT), 173–177,
 262–263, 329–330
- Epithelium
- adherens junctions, 140
- sheet migration, 171
- desmosomes, 140–141
- epidermis. *See* Epidermis
- intestinal epithelium. *See also* Intestinal mucosa
 cell migration and cell–cell junctions, 147
 cell proliferation and adherens junction/tight
 junction function, 144, 146
 epidermal cell–cell junction comparison,
 153–154
 overview, 141
 permeability barrier and tight junction function,
 141–144
 organization, 137–138

stratified epithelium polarity and junctions,
192–193
tight junctions, 138–140
EPS8, 311
ER. *See* Estrogen receptor
Erbin, 195
ERK1/2, 100
Erythrokeratoderma variabilis et progressiva, 352
ESAM, 221, 224
Estrogen receptor (ER), 335
Ets-2, 117
Ex, 36, 38, 45

F

F-Actin
adherens junction
cadherin/catenin complex
adapter protein interplay, 12
components and regulation, 10–12
core complex, 3–5
dynamics, 12–14
force-dependent anchoring to F-actin, 8–10
prospects for study, 14
cadherin clustering
F-actin association, 6–8
microclusters, 6–8
overview, 5–6
Hippo signaling modulation, 45
FAK. *See* Focal adhesion kinase
Fat, 41, 188, 281
FGD5, 314
FGF. *See* Fibroblast growth factor
FGFR. *See* Fibroblast growth factor receptor
Fibroblast growth factor (FGF), 262
Fibroblast growth factor receptor (FGFR), 209, 211, 312
Filamin-A, 83
FILGAP, 31
Fluorescence recovery after photobleaching (FRAP)
adherens junction cadherin/catenin complex
studies, 5–6, 73
E-cadherin recycling studies, 73
Fluorescence resonance energy transfer (FRET),
mechanical force measurement, 60–61
Focal adhesion kinase (FAK), 44, 119, 121, 267
Focal adhesion, Hippo signaling modulation, 44–45,
96, 123, 152
FoxP2, 280
FRAP. *See* Fluorescence recovery after photobleaching
FRET. *See* Fluorescence resonance energy transfer
Fzd3, 281, 284

G

Gα13, 310–311
γ-Catenin. *See* Plakoglobin

Gap junction
axon guidance
ephrin regulation, 114
netrin regulation, 122–123
overview, 110
semaphorin regulation, 118
connexins
mutations
cancer, 348–349
deafness, 352–353
heart disease, 354–355
neurological disorders, 349–350
oculodentodigital dysplasia, 346–348
overview, 347
skin diseases, 351–352
structure and organization, 345–346

GAPs. *See* GTPase-activating proteins

Gastric cancer, E-cadherin loss, 328

GEFs. *See* Guanine nucleotide exchange factors

GIT1, 127

GSK-3, 146, 151, 154, 210

GTPase-activating proteins (GAPs), epithelial junction
proteins, 25–27

GTPases. *See also specific GTPases*

activation, 20–21, 28–30

cytoskeletal structures as platform for signaling
complexes, 30–31

epithelial junction proteins, 22–24

localization, 21, 27–29

Guanine nucleotide exchange factors (GEFs), epithelial
junction proteins and effectors, 20, 22–27

H

Hair cell

cadherin types, 235–236

connexin mutations, 352–353

mechanotransduction and cadherin tip links

cadherin mutations and diseases, 247–248

elasticity of tip link, 244, 249–250

gating spring model, 238–239

genetic determinants of function

cadherin-23, 245–247

protocadherin-15, 245–247

overview, 236–238

prospects for study, 252–253

protocadherin-15 linkage mechanism, 250–252

strength of tip link, 248–249

structural determinants of function

cadherin-23, 239–241

protocadherin-15, 241–243, 245

Hakai, 76

Hearing. *See* Deafness; Hair cell

HED. *See* Hidrotic ectodermal dysplasia

HEG1, 311–312, 314

Hepatocyte growth factor (HGF), 31, 206–207

Index

- Hes1, 271
Hey1, 271–272
HeyL, 271–272
HGF. *See* Hepatocyte growth factor;
Human growth factor
Hidrotic ectodermal dysplasia (HED), 351–352
Hindsight, 175
Hippo signaling
 adherens junctions in signaling
 Ajuba, 42
 cadherin/catenin core complex, 42
 loss of adherens junctions effects, 43–44
 Merlin, 43
 NF2, 43
 overview, 41–42
 Pez, 43
 PTPN14, 43
 cytoskeletal regulation
 actin structural changes, 45
 cellular tension in regulation, 46
 spectrins, 45–46
 focal adhesion studies, 44–45
 mechanotransduction, 66
 netrins, 123
 overview, 35–38
 pathology of cell junction-dependent regulation,
 46–47
 tight junctions in signaling
 angiotensin proteins, 39–40
 atypical protein kinase C polarity
 module, 40
 Crumbs complex, 38–39
 Dachsous, 41
 Fat, 41
 overview, 38
 zonula occludens proteins, 40
 wound healing, 153
Histamine, 310
Hsp27, 101
Human growth factor (HGF), 75
- I**
- IBD. *See* Inflammatory bowel disease
IgCAMs. *See* Immunoglobulin-like cell adhesion
 molecules
IL-13. *See* Interleukin-13
ILK, 44
Immunoglobulin-like cell adhesion molecules
 (IgCAMs), cell migration functional
 overview, 168
Inflammatory bowel disease (IBD), 143–144,
 296–297, 300
Integrins
 cell migration functional overview, 169
 myoblast fusion, 169
Interleukin-13 (IL-13), tight junction permeability
 regulation in intestinal mucosa,
 298–299
Intestinal epithelium. *See* Epithelium; Intestinal mucosa
Intestinal mucosa
 anatomy, 292–293
 cell junction overview, 293–294
 tight junctions
 permeability regulation
 interleukin-13, 298–299
 occludin, 300–301
 pore and leak pathways, 299–300
 tumor necrosis factor- α , 296–299
 prospects for study, 301–302
 structure, 294–296
IQGAP1, 210
- J**
- JAM, 140, 143, 167, 225, 268
Jing, 175
JLP, 265
JNK, 100, 126, 169
JUP, 333
- K**
- Keratin
 desmosome interactions, 98–101
 filament composition, assembly, and organization,
 96–97
 pathology, 97–98
Keratinocyte. *See also* Epidermis
 adherens junction in proliferation, 152
 wound healing, 152
Keratoderma-hypotrichosis-leukonychia totalis
 syndrome, 352
Khc-73, 79
Kib, 38, 46
KIBRA, 40
KID syndrome, 351, 353
Kif13A, 79
KIF17, 31
KifC3, 79
Kir2.1, 267
Kirrel, 268
KRT1, 97–98
KRT2e, 97
KRT5, 97–99, 101
KRT6, 97
KRT6, 99
KRT8, 98, 100–101
KRT9, 97
KRT10, 97–98
KRT14, 97–98, 100–101
KRT16, 97

- KRT17, 97, 99
 KRT18, 100–101
 KRT19, 97, 100
 KSRP, 266
- L**
- LARG, 315
 LATS1/2, 36, 39–40, 42, 44, 47
 LEE, 152
 Leukocyte swarming, 172–173
 Lgl, 77
 Lgr5, 293
 LIMD1, 42
 Lipoma preferred partner (LPP), 11
 LPP. *See* Lipoma preferred partner
- M**
- Mammalian target of rapamycin complex (mTORC), 31
 Mats, 35
 M-Cadherin, myoblast fusion, 169
 Mechanical force. *See also* Hair cell
 cadherin/catenin complex mechanotransduction
 consequences
 early, 64–65
 late, 65–66
 desmosome
 keratin complex and effects of mechanical
 stretch, 100
 mechanosensing, 101–102
 mechanotransduction, 95–96, 102
 external forces on cell–cell junctions, 56
 measurement, 58–60
 mechanosensing
 cadherin/catenin complex, 61–63
 cytoskeleton, 63–64
 propagation, 58
 tissue-generated forces on cell–cell junctions
 cell contraction, 56–57
 osmotic force, 57–58
- MEF2, 262, 285
 MEKK3, 316
 Meltrin, 169
 Merlin, Hippo signaling modulation, 35, 41, 43, 45–46
 Metastasis, collective migration and tuning, 175–176
 MgcRacGAP, 30
 MicroRNA
 neurogenesis regulation, 281
 Slit/Robo regulation of tight junctions, 127–128
- MKK6, 266–267
 MLCK, 144, 147, 296–300
 MMP-9, 127–128
 Mnb, 41
 Morphogenesis. *See also* Angiogenesis
 cell sheet and cluster migration, 171–172
 collective migration and tuning, 173–175
 sprouting strands, 171
- MRCK, 314
 MRF4, 261
 MRTF-A, 95
 mTORC. *See* Mammalian target of rapamycin complex
 Mucosa. *See* Intestinal mucosa
 Muscle. *See* Myogenesis, skeletal muscle
 Myf5, 261–265
 MyHC, 269–270
 Myoblast fusion, 169, 171, 265–269
 MyoD, 261–262, 266–267
 Myofiber, formation, 169, 171
 Myogenesis, skeletal muscle
 muscle fiber type patterning, 269–270
 myoblast differentiation and fusion, 265–269
 overview, 261–262
 progenitor cell commitment, 262–265
 prospects for study, 272–273
 satellite cell–myofiber interactions, 270–272
- Myomaker, 268
 Myosin II, 8, 12, 64
- N**
- N-Cadherin, 263, 265
 history of study, 2
 myoblast fusion, 169
 neurogenesis, 280–285
- NCAM. *See* Neural cell adhesion molecule
 Nck1, 112–113, 119
 Nck2, 112, 169
 NEC. *See* Neuroepithelial cell
 NELL2, 126
 Neogenin, 120
 Nephrin, 268
 Nesprin, 46
 Netrin
 adherens junction regulation, 120–122
 gap junction regulation, 122–123
 overview, 118–120
 receptors, 118–120
 tight junction regulation, 122
- Neural cell adhesion molecule (NCAM),
 myoblast fusion, 169
 Neural crest cell, migration, 172
 Neural progenitor cell (NPC), 280
 Neuroepithelial cell (NEC), 279–281
 Neurogenesis
 axon extension, targeting, and arborization,
 282–284
 differentiation, 279–280
 migration, 281–283
 overview, 277–279
 prospects for junction studies, 286–287
 synaptogenesis, 284–286

Index

- NF- κ B. *See* Nuclear factor- κ B
NF2, Hippo signaling modulation, 35, 41, 43, 46
NFAT3, 267
NMII. *See* Nonmuscle myosin II
Nonmuscle myosin II (NMII), 56
Notch, 221, 263–264, 272
NOX, 313
NPC. *See* Neural progenitor cell
Nrf2, 101
NRP-1, 116–118
NRP-2, 116
Nuclear factor- κ B (NF- κ B), 152
Numb, E-cadherin recycling studies, 73
- O**
- Occludin, 127, 139
 structure, 294–295
 tight junction permeability regulation in intestinal
 mucosa, 300–301
Oculodentodigital dysplasia (ODDD), 346–348
ODDD. *See* Oculodentodigital dysplasia
- P**
- p38, 265–267
p53, 329, 331
p114RhoGEEF, 28–29
p120 catenin
 adherens junction cadherin/catenin complex
 adapter protein interplay, 12
 components and regulation, 10–12
 core complex, 3–5
 dynamics, 12–14
 force-dependent anchoring to F-actin, 8–10
 prospects for study, 14
 adhesive strength modulation, 95
 cancer defects, 331, 335
 E-cadherin endocytosis inhibition, 75
 evolution, 189–190
 receptor tyrosine kinase impact, 206
p150, 123
p190RhoGAP-A, 30
PACSIN, 21
PAK, 206, 265
Palmoplantar keratoderma with deafness (PPK), 351
Pals1, 222, 225
Pancreatic cancer, E-cadherin loss, 328–329
PAR3, 225–226, 331, 333
PAR6, 225, 331
Par6, E-cadherin endocytosis role, 74, 76–78
Patj, 38, 222
P-Cadherin, 151, 193, 265, 327–328
PCDH15. *See* Protocadherin-15
PCDH21. *See* Protocadherin-21
PCDH24. *See* Protocadherin-24
PECAM-1, 221, 228–229, 312
Pelizaeus–Merchbacher-like disease, 350
Pez, Hippo signaling modulation, 43
PG, 94, 99, 101–102
PI3K, 225, 337
PKP. *See* Plakophilin
PKP1, 90–94, 194, 189, 193–194
PKP2, 90–93, 96, 193–195
PKP3, 90–95, 193, 195, 333
PKP4, 90, 333
Plakoglobin, 190, 333
Plakophilin (PKP), 141, 149, 188, 190, 193, 333
Plexin, 115–118
PPK. *See* Palmoplantar keratoderma with deafness
PRMT-1, 154
Protein kinase C. *See* Atypical protein kinase C
Protocadherin-7, 283
Protocadherin-8, 285
Protocadherin-10, 281, 284
Protocadherin-11, 281
Protocadherin-15 (PCDH15)
 genetic determinants of function, 245–247
 hair cell mechanotransduction overview, 236–238
 mechanotransduction linkage mechanism, 250–252
 mutations and diseases, 247–248
 structural determinants of function, 241–243, 245
Protocadherin-17, 281, 284–286
Protocadherin-19, neurogenesis, 281–282
Protocadherin-21 (PCDH21), 235
Protocadherin-24 (PCDH24), 235
PSD-95, 38, 111, 285
PTEN, 225
PTPN14, Hippo signaling modulation, 43
PVR, 209, 211
Pyk2, 313
- R**
- Rab4, 79
Rab5, 73, 78
Rab11 endosomes, E-cadherin trafficking
 recycling role, 79
 sorting of newly synthesized E-cadherin, 80–81
Rac1, 112, 225, 227, 229, 334
 cytoskeletal structures as platform for signaling
 complexes, 30–31
 guanine nucleotide exchange factors, 27
Radial glial cell (RGC), 279–281
Radil, 227
Raf1, 222
Rap1, 95, 222, 313–314
Ras, 334
Rasip1, 314
RASSE, 40
RBP-J, 271–272
Receptor tyrosine kinase (RTK). *See also specific receptors*

effects in cell junctions
 adherens junction local impact, 206–207, 209
 tissue-scale impact, 209–210
functional overview, 205–206
modulation by cell junctions
 direct interactions, 211
 mechanical control by cell junctions, 211, 213
 spatial control by junctional cues, 210–212
prospects for study, 213–214
 VE-cadherin interactions, 312–313
RGC. *See* Radial glial cell
RhoA
 activation, 20–21
 adherens junction regulation, 195
 cytoskeletal structures as platform for signaling
 complexes, 30
 guanine nucleotide exchange factors, 27
 localization of activation, 27
 mechanotransduction, 64–65
 tight junction regulation, 167
RhoG, 314
RhoGDI, 20–21
Rich1, 222
Riq, 41
Robo1, 126–127
Robo2, 126–127
Robo3, 126
Robo4, 121, 124, 127–128
ROCK, 147, 314–316, 318, 335
ROCK1, 57, 64, 334
RTK. *See* Receptor tyrosine kinase
Runx1, 146

S

SAM syndrome. *See* Sinobrachial allergic mycosis syndrome
Satellite cell, myofiber interactions, 270–272
Scrib, 81, 83
Sdt, 38
Sec5, 79
Sec6, 79
Sec15, 79
Semaphorin
 adherens junction regulation, 117
 gap junction regulation, 118
 overview, 114–115
 receptors, 112, 115–117
 tight junction regulation, 117–118
Serum-response factor (SRF), 95
SG2 tight junction. *See* Tight junction
SGLT1, 293
Shh. *See* Sonic hedgehog
SHO, 122
SHOC2, 195
SHP2, 206

Sinobrachial allergic mycosis (SAM) syndrome, 92–93
SIX4, 175
Slit
 adherens junction regulation, 125–127
 cell migration functional overview, 168
 overview, 123–125
 receptors, 124
 tight junction regulation, 127–128
SNAIL, 26, 117
Snx1, 79
Snx4, 79
SOLO, 31
Sonic hedgehog (Shh), 262
Sox2, 280
SoxB1, 280
Spectrins, Hippo signaling modulation, 45–46
Sphingosine-1-phosphate, 229
SPINT1, 99
Sprouting. *See* Angiogenesis
Src, 169, 206, 230
Src42A, 76
SRF. *See* Serum-response factor
STRIPAK, 316
SUMO, 76
SWI-SNF, 266
Syndecan-2, 127
Syx, 222

T

Tak1, 265
TAZ, Hippo signaling, 35–36, 39, 44, 65, 96, 102
T-cell factor (TCF), 262, 265, 334–335
TCF. *See* T-cell factor
TEAD, 96, 102
TIAM1, 229
Tiam1, 28, 30–31, 167
Tie2, 226, 230, 313
Tight junction (TJ)
 axon guidance
 ephrin regulation, 114
 netrin regulation, 122
 overview, 110
 semaphorin regulation, 117–118
 Slit/Robo regulation, 127–128
 cancer defects, 331, 333
 cell migration functional overview, 167–168
 epithelium
 epidermal barrier function, 147, 149–151
 intestinal epithelium cell proliferation, 144,
 146–148
 intestinal epithelium permeability barrier,
 141–144
 overview, 138–140
 SG2 tight junction barrier formation, 194, 197–198
TJ. *See* Tight junction

Index

- TNF- α . *See* Tumor necrosis factor- α
Tricellin, 295
Trio, 30, 310
TSA Δ , 221
Tuba, 28
Tumor necrosis factor- α (TNF- α), tight junction
 permeability regulation in intestinal
 mucosa, 296–299
Twist, 176
- U**
- UNC5, 119, 121, 123–124
Usherin, 236
- V**
- Vascular endothelial growth factor (VEGF), 124–125,
 206, 213, 220–222, 310
Vascular remodeling
 flow sensing and junction proteins, 228
 overview, 227–228
 pruning and junction rearrangement, 228–229
VASP, 284
VAV2, 169, 229
Vav3, 169
VCAM-1, myoblast fusion, 169
VE-Cadherin
 angiogenic sprouting
 actin cytoskeleton organization and sprout
 elongation, 222
 cessation of sprouting, 224
 vascular endothelial growth factor regulation of
 turnover, 221
 endothelial adherens junctions
 interactions
 Tie2, 313
 tyrosine kinase receptors, 312–313
 VE-PTP, 313
 overview, 308–310
 Hippo signaling modulation, 42
 mechanical force, 56
VE-PTP, 230, 313
VEGF. *See* Vascular endothelial growth factor
VEGFR2, 206, 211, 213, 221–222, 224, 229, 310,
 312–313
VEGFR3, 213, 312
VHL, 316
Vinculin, adherens junction cadherin/catenin complex
 adapter protein interplay, 12
 components and regulation, 10–12
 core complex, 3–5
 dynamics, 12–14
 force-dependent anchoring to F-actin, 8–10
 mechanosensing, 63–64
 prospects for study, 14
VLGR1, 236
- W**
- WASP, 77
WAVE complex, 83, 121, 284
WD40, 41
Wnt, 146, 281, 286–287, 334–335
Wound healing
 adherens junction role, 152–153
 Hippo signaling, 153
WTIP, 42
Wts, 38, 41, 66
- Y**
- Yan, 175
YAP
 cancer studies, 334
 endothelial junction interactions, 311
 epithelium, 146, 153
 Hippo signaling, 35–36, 39–40, 42–46, 65,
 96, 102, 123
Yes, 44
Yki, Hippo signaling, 35–36, 38, 42–46, 65–66
- Z**
- ZA. *See* Zonula adherens
Zeb1, 176
ZO. *See* Zonula occludens
ZO-1, 300–301, 331
 axon guidance, 122, 127
 epithelium, 139–140, 144, 147, 149, 154
 Hippo signaling modulation, 38, 40
 intestinal mucosa, 294
 vessel anastomosis, 223
ZO-2
 epithelium, 139, 144, 149, 153
 Hippo signaling modulation, 40
 mutations, 296
ZO-3
 epithelium, 139, 149
 Hippo signaling modulation, 40
ZONAB, 139, 144, 146
Zonula adherens (ZA), 57, 64, 186
Zonula occludens (ZO), 11–12
Zyxin, 45